NICE confirms Bydureon recommendation

 NICE has confirmed its recommendation of Eli Lilly’s prolonged release Bydureon (exenatide) for people with type 2 diabetes in final draft guidance.

The guidance recommends the injection as part of triple or dual therapy regimen for patients when their control of blood glucose remains or becomes inadequate in certain circumstances.

Professor Carole Longson, Health Technology Evaluation Centre Director at NICE, says that the estimated 2.25 million people in the UK need as many effective treatments as possible to control the condition.

The injection improves glycaemic control by lowering the rise in blood sugar as a result of eating and prevents hyperglycaemia.

In triple therapy regimens in combination with metformin and a sulphonylurea, or metformin and thiazolidinedione, Bydureon is recommended if a person has a certain body mass index (BMI) and has specific psychological or medical problems associated with their weight, or if therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.

Bydureon is recommended in dual therapy regimens in combination with metformin or a sulphonylurea if either of the two together or separately is contraindicated or not tolerated or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated or not tolerated.

NICE says that treatment with the injection for both triple and dual therapy regimens should only be continued if a beneficial metabolic response has been proven.

Metformin, sulphonylureas and thiazolidinediones are other treatments used to lower glucose levels in the blood in the management of type 2 diabetes mellitus.